Protein C News and Research

RSS

Novel method of disguising nanoparticles as red blood cells to fight cancer

Researchers at the University of California, San Diego have developed a novel method of disguising nanoparticles as red blood cells, which will enable them to evade the body's immune system and deliver cancer-fighting drugs straight to a tumor. Their research was published this week in the online Early Edition of the Proceedings of the National Academy of Sciences.

22 Jun 2011

Caffeinated coffee boosts blood GCSF levels, protects against Alzheimer's

A yet unidentified component of coffee interacts with the beverage's caffeine, which could be a surprising reason why daily coffee intake protects against Alzheimer's disease.

22 Jun 2011

TESARO secures $101M in Series B financing

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio.

21 Jun 2011

NextGen launches first CSF multiplex protein assay for detecting CNS diseases

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification.

21 Jun 2011

Johns Hopkins scientists develop mouse model for autism spectrum disorders

In an effort to unravel the tangled biology of autism, Johns Hopkins scientists have created a mouse model that mimics a human mutation of a gene known to be associated with autism spectrum disorders.

21 Jun 2011

Free ADAP 2.0 software upgrade with Biochrom's EZ Read 400 research reader

Busy laboratory environments require a microplate reader with the flexibility to cover many assay types, and software that delivers fast, reliable analysis. With this in mind, Biochrom are offering a free software upgrade from ADAP 2.0 Basic to ADAP 2.0 Plus with purchases of the EZ Read 400 research reader until 30 September 2011. For further information, visit www.biochrom.co.uk.

From Biochrom Ltd. 20 Jun 2011

Breakthrough treatment for Cystic Fibrosis sufferers with 'Celtic Gene'

An international research team led by Queen's University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the 'Celtic Gene', a genetic mutation which is particularly common in Ireland.

20 Jun 2011

Genetic biomarker may help identify patients at increased risk of bypass surgery

Outcomes of bypass surgery to repair blocked arteries in the legs tend to be better in the roughly one-in-five people who have inherited a specific genetic variation from both parents, according to a study presented at the late-breaking clinical trials session of the Vascular Annual Meeting in Chicago on June 18, 2011.

20 Jun 2011

Panacea Global announces name change

Panacea Global Inc.,, a biopharmaceutical company specializing in blood (protein), serum and tissue tests to diagnose and monitor cancer, today announced the change of the Company's official trading symbol from MLXG to PANG.

20 Jun 2011

Randox launches automated laboratory assay for Heart-type Fatty Acid Binding Protein

Randox Laboratories, the international clinical diagnostics company, has today launched an automated laboratory assay for Heart-type Fatty Acid Binding Protein (H-FABP), to improve the diagnosis and management of patients with suspected acute coronary syndrome (ACS).

From Randox Laboratories Ltd. 20 Jun 2011

IsoRay announces combination therapy study for prostate cancer

IsoRay Inc., announced today a new dual therapy study using Cesium-131 brachytherapy (internal radiation therapy) and external beam radiation. Multiple sites have now received Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT) with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.

20 Jun 2011

Ground breaking treatment for Cystic Fibrosis

20 Jun 2011

Researchers identify nine blood proteins that alter with age

Loss of muscle mass is not only associated with disease, such as HIV and cancer, but also with the normal aging process. Anabolic steroids are sometimes used to reverse loss of lean muscle tissue but they can have unwanted side effects.

20 Jun 2011

Novel biomarker-development pipeline approach for human diseases

Researchers at Fred Hutchinson Cancer Research Center have demonstrated in mice that the performance of a novel biomarker-development pipeline using targeted mass spectrometry is robust enough to support the use of an analogous approach in humans.

20 Jun 2011

Novel vaccine approach for prostate cancer

Mayo Clinic investigators and collaborators from the United Kingdom cured well-established prostate tumors in mice using a human vaccine with no apparent side effects. This novel cancer treatment approach encourages the immune system to rid itself of prostate tumors without assistance from toxic chemotherapies and radiation treatments.

20 Jun 2011

Researchers use DNA library to create potential cancer vaccine

University of Leeds researchers, funded by Cancer Research UK, have used a library of DNA to create a vaccine that could be used to treat cancer, according to a study published in Nature Medicine.

20 Jun 2011

Scientists discover linchpin protein that drives mitochondria's calcium machinery

Mitochondria, those battery-pack organelles that fuel the energy of almost every living cell, have an insatiable appetite for calcium. Whether in a dish or a living organism, the mitochondria of most organisms eagerly absorb this chemical compound.

20 Jun 2011

Scientists discover three susceptibility genes for development of progressive supranuclear palsy

An international research team, co-led by scientists at Mayo Clinic's campus in Florida, have discovered three potential susceptibility genes for development of progressive supranuclear palsy (PSP), a rare neurodegenerative disease that causes symptoms similar to those of Parkinson's disease but is resistant to Parkinson's medications.

20 Jun 2011

New insight into progressive supranuclear palsy

There are new genetic clues on risk factors and biological causes of a rare neurodegenerative disease called progressive supranuclear palsy (PSP), according to a new study from an international genetics team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

20 Jun 2011

Genomic study identifies MCU that regulates calcium transport into mitochondria

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Massachusetts General Hospital (MGH), the Broad Institute, and the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), today announced new findings published in Nature.

20 Jun 2011